Authors' recommendations: Eribulin mesilate (Halaven®) is licensed for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. Eribulin mesilate (Halaven®) is recommended as an option for restricted use within NHS Wales after at least two prior chemotherapeutic regimens for advanced disease which includes capecitabine. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. Eribulin mesilate (Halaven®) is not recommended for use within NHS Wales outside of these circumstances.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.awmsg.org/awmsgonline/app/appraisalinfo/1212

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Wales, United Kingdom

Organisation Name: All Wales Medicines Strategy Group

Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX

Contact Name: AWTTC@wales.nhs.uk

Contact Email: AWTTC@wales.nhs.uk

Copyright: AWTTC